Cross-Sectional Study of Association Between Glycemic Control and Quality of Life Among Diabetic Patients

Natasya, Anita; Andrajati, Retnosari; Sauriasari, Rani

doi:10.22159/ijap.2018.v10s1.19

Cited by 6 publications

(8 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18 In two studies that were conducted in Indonesia, the mean health utility of patients with type 2 diabetes was 0.74 and 0.77, respectively. 19,20 Compared to these previous findings, the results of the present study, determined there was a health utility value of 0.294 ± 0.371, which is quite low. Moreover, this low health utility value was found to improve in conjunction with the healing.…”

Section: Discussioncontrasting

confidence: 95%

Impact of foot ulcer‐related factors on quality of life in patients with diabetes: Prospective observational study

Oe,

Saad,

Jais

et al. 2024

International Wound Journal

View full text Add to dashboard Cite

Quality of life (QOL) may be impacted by foot ulcer‐related factors, with prevention of diabetes‐related foot ulcers or more effective early healing helping to improve overall patient QOL. This study, which examined the relationship between foot ulcer‐related factors and QOL in patients with diabetes, was conducted as a secondary analysis of a prospective observational study entitled: “Factors associated with the discontinuation of wound care specialist clinic visits in patients with diabetic foot ulcers”. We investigated EQ‐5D‐5L, patient characteristics and foot ulcer‐related factors of 73 patients with diabetes‐related foot ulcers who visited one wound clinic in Indonesia between August 2020 and February 2021. Results showed that the mean health utility was 0.294 ± 0.371. Factors selected for the multiple regression analysis included inflammation/infection of DMIST, first‐ever foot ulcer, and size of DMIST. First‐ever foot ulcer (β = 0.309, p = 0.003) and size of DMIST (β = −0.316, p = 0.015) were significantly associated with the health utility (p < 0.001). Significant improvement in the health utility of 15 patients was observed when the ulcer healed (Wilcoxon signed‐rank sum test, p = 0.001). In conclusion, not only ulcer severity but also the first‐ever foot ulcer itself affected the QOL in patients with diabetes. These results suggest there will be a greater impact on the QOL of patients who develop diabetes‐related foot ulcers for the first time, along with the importance of prevention and early healing, through early infection control and wound size reduction.

show abstract

Section: Discussioncontrasting

confidence: 95%

Impact of foot ulcer‐related factors on quality of life in patients with diabetes: Prospective observational study

Oe,

Saad,

Jais

et al. 2024

International Wound Journal

View full text Add to dashboard Cite

show abstract

“…For patients with diabetes mellitus (Table 2), 12 studies reported health utility values ranging from 0.31 to 0.99 (14,15,(18)(19)(20)(21)(22)(23)(24)(25)(26)(27). The Chinese standard EQ-5D-5L value set (18) and Crosswalk UK value set (24) were used to derive the utility values in the studies that reported the highest value and lowest value, respectively.…”

Section: Diabetes Mellitusmentioning

confidence: 99%

“…The results showed that the utility value calculated with the Uruguay value set was the highest at 0.880, while the lowest, 0.735, was derived with the value set from the Netherlands. The EQ-5D VAS scores were reported to range from 50.9 to 72.6 in six studies (14,20,(22)(23)(24)(25). Among the five dimensions of the EQ-5D-5L, pain/discomfort was the dimension with the most reported problems.…”

Section: Diabetes Mellitusmentioning

confidence: 99%

See 1 more Smart Citation

Health-Related Quality of Life in Patients With Different Diseases Measured With the EQ-5D-5L: A Systematic Review

Zhou

Guan

Wang

et al. 2021

Front. Public Health

View full text Add to dashboard Cite

Background: The EQ-5D-5L is a generic preference-based questionnaire developed by the EuroQol Group to measure health-related quality of life (HRQoL) in 2005. Since its development, it has been increasingly applied in populations with various diseases and has been found to have good reliability and sensitivity. This study aimed to summarize the health utility elicited from EQ-5D-5L for patients with different diseases in cross-sectional studies worldwide.Methods: Web of Science, MEDLINE, EMBASE, and the Cochrane Library were searched from January 1, 2012, to October 31, 2019. Cross-sectional studies reporting utility values measured with the EQ-5D-5L in patients with any specific disease were eligible. The language was limited to English. Reference lists of the retrieved studies were manually searched to identify more studies that met the inclusion criteria. Methodological quality was assessed with the Agency for Health Research and Quality (AHRQ) checklist. In addition, meta-analyses were performed for utility values of any specific disease reported in three or more studies.Results: In total, 9,400 records were identified, and 98 studies met the inclusion criteria. In the included studies, 50 different diseases and 98,085 patients were analyzed. Thirty-five studies involving seven different diseases were included in meta-analyses. The health utility ranged from 0.31 to 0.99 for diabetes mellitus [meta-analysis random-effect model (REM): 0.83, (95% CI = 0.77–0.90); fixed-effect model (FEM): 0.93 (95% CI = 0.93–0.93)]; from 0.62 to 0.90 for neoplasms [REM: 0.75 (95% CI = 0.68–0.82); FEM: 0.80 (95% CI = 0.78–0.81)]; from 0.56 to 0.85 for cardiovascular disease [REM: 0.77 (95% CI = 0.75–0.79); FEM: 0.76 (95% CI = 0.75–0.76)]; from 0.31 to 0.78 for multiple sclerosis [REM: 0.56 (95% CI = 0.47–0.66); FEM: 0.67 (95% CI = 0.66–0.68)]; from 0.68 to 0.79 for chronic obstructive pulmonary disease [REM: 0.75 (95% CI = 0.71–0.80); FEM: 0.76 (95% CI = 0.75–0.77)] from 0.65 to 0.90 for HIV infection [REM: 0.84 (95% CI = 0.80–0.88); FEM: 0.81 (95% CI = 0.80–0.82)]; from 0.37 to 0.89 for chronic kidney disease [REM: 0.70 (95% CI = 0.48–0.92; FEM: 0.76 (95% CI = 0.74–0.78)].Conclusions: EQ-5D-5L is one of the most widely used preference-based measures of HRQoL in patients with different diseases worldwide. The variation of utility values for the same disease was influenced by the characteristics of patients, the living environment, and the EQ-5D-5L value set.Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42020158694.

show abstract

“…2) with molecular formula C 4 H 11 N 5 .HCl. The main mechanism of metformin HCl was lowering glucose intestinal absorption, inhibition of hepatic glucose production, and improving glucose uptake and utilization [1][2][3][4][5][6].…”

Section: Introductionmentioning

confidence: 99%

Validation of a Developed Analytical Method for Determination of Nateglinide and Metformin HCL in Pure and Pharmaceutical Dosage Form by Reversed-Phase High-Performance Liquid Chromatography and Its Degradation Studies

Ismail¹,

Rao²

2021

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: The objective of the study was to develop a versatile analytical method and validate according to International Council for Harmonization guidelines for simultaneous estimation of nateglinide and metformin HCl by reversed-phase high-performance liquid chromatography (RP-HPLC) in active pharmaceutical ingredient and in tablet dosage form. Methods: Analytes, metformin and nateglinide, are separated and eluted from stationary phase luna phenyl hexyl column (150 mm ×4.6 mm, 3.5 μm) (micrometer) using polar mobile phase composed of acetonitrile:1% orthophosphoric acid 30:70 v/v, with flow rate of 1 ml/min for 8 min at ambient column temperature, at 221 nm (nanometer) detection. Acid, base, peroxide, thermal, and photolytic-induced degradation studies were performed on nateglinide and metformin. Results: Through isocratic flow, both metformin and nateglinide are detected at retention times of 2.79 min and 5.13 min, respectively, at 221 nm. The linearity and range of analytical method for nateglinide and metformin were 0.61–9.15 μg/ml and 7.5–75.15 μg/ml, respectively. The R2 value for nateglinide was 0.9998 and for metformin HCl was 0.9991. The limit of detection and limit of quantification for nateglinide were 0.21 μg/ml and 0.63 μg/ml and for metformin were 4.8 μg/ml and 14.6 μg/ml, respectively. The % relative standard deviation for method precision was found to be 0.22% and 0.64% for both nateglinide and metformin, respectively. The mean %recovery for nateglinide and metformin was 99.88% and 99.21%, respectively. The %thermal degradation was identified as 17.7% and 17.5% for nateglinide and metformin, respectively. Conclusion: The developed chromatographic (RP-HPLC) method was selective, specific, economic, precise, and accurate. Hence, it can be one of the preferred analytical methods of choice for the estimation of nateglinide and metformin by RP-HPLC in pure and in tablet dosage form.

show abstract

Cross-Sectional Study of Association Between Glycemic Control and Quality of Life Among Diabetic Patients

Cited by 6 publications

References 16 publications

Impact of foot ulcer‐related factors on quality of life in patients with diabetes: Prospective observational study

Impact of foot ulcer‐related factors on quality of life in patients with diabetes: Prospective observational study

Health-Related Quality of Life in Patients With Different Diseases Measured With the EQ-5D-5L: A Systematic Review

Validation of a Developed Analytical Method for Determination of Nateglinide and Metformin HCL in Pure and Pharmaceutical Dosage Form by Reversed-Phase High-Performance Liquid Chromatography and Its Degradation Studies

Contact Info

Product

Resources

About